Tesofensine

Tesofensine is a non-peptide compound investigated for its effects on monoamine signaling and body-weight regulation. Initially explored in neurodegenerative disease research, it subsequently became a candidate for obesity-related investigation.

Serotonin, norepinephrine, and dopamine participate in neural pathways involved in feeding behavior, motivation, and alertness. The notes link tesofensine's early development to research on Alzheimer’s and Parkinson’s diseases, followed by interest in its potential effects on food intake and weight.

Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine, affecting the availability of these neurotransmitters for signaling. This mechanism has been investigated in relation to appetite regulation and changes in body weight. The guide also proposes effects on energy expenditure and fat metabolism, but the supplied material does not establish these as independently demonstrated mechanisms.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents reduced appetite and body weight as major reasons for interest in tesofensine. It additionally attributes possible changes in alertness, concentration, and metabolic status to the compound, without supplying supporting study details. Although the guide characterizes tolerability favorably, it also identifies gastrointestinal, cardiovascular, and other potential adverse effects.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The supplied notes do not establish the magnitude, durability, or clinical significance of the proposed benefits. They also leave unclear whether changes in metabolic outcomes or perceived energy occur independently of reduced food intake or weight change.

Potential adverse effects described in the guide include nausea, difficulty passing stools, oral dryness, headache, and increases in pulse or blood pressure. Safety data are limited in the supplied material, particularly for long-term outcomes and for people with cardiovascular or psychiatric conditions or sensitivity to stimulants. This information is not medical advice; individualized safety concerns require assessment by a qualified healthcare professional.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Tesofensine weight loss and appetite suppression”
• “Tesofensine SNDRI clinical trials”
• “Tesofensine for metabolic regulation”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN